Enhancing cancer treatment by targeting immune cell metabolism
Metabolic Reprogramming of Myeloid Cells to Enhance Cancer Immunotherapy
['FUNDING_OTHER'] · ROSWELL PARK CANCER INSTITUTE CORP · NIH-10984187
This study is looking at how to make cancer treatments work better by focusing on certain immune cells that can hold back the body's fight against tumors, and it aims to find new ways to help patients by testing these ideas in mice.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ROSWELL PARK CANCER INSTITUTE CORP (nih funded) |
| Locations | 1 site (BUFFALO, UNITED STATES) |
| Trial ID | NIH-10984187 on ClinicalTrials.gov |
What this research studies
This research investigates how to improve cancer immunotherapy by focusing on myeloid cells, which can suppress the immune response against tumors. The approach involves using specific inhibitors to target the metabolism of these immune cells, potentially enhancing the effectiveness of existing cancer treatments. By studying this in mouse models, the researchers aim to identify ways to reduce tumor growth and improve patient outcomes. The ultimate goal is to develop strategies that can be translated into clinical settings for better cancer therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia or those with cancers that exhibit a strong immune suppressive response.
Not a fit: Patients with cancers that do not involve myeloid cell suppression or those who are not eligible for immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that improve survival rates for patients with aggressive cancers like acute myeloid leukemia.
How similar studies have performed: Other research has shown promising results in targeting immune cell metabolism to enhance cancer therapies, suggesting that this approach may be effective.
Where this research is happening
BUFFALO, UNITED STATES
- ROSWELL PARK CANCER INSTITUTE CORP — BUFFALO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MORREALE, BRIAN GEORGE — ROSWELL PARK CANCER INSTITUTE CORP
- Study coordinator: MORREALE, BRIAN GEORGE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.